In silico identification and crystal structure validation of caspase-3 inhibitors without a P1 aspartic acid moiety.

Using a fragment-based docking procedure, several small-molecule inhibitors of caspase-3 were identified and tested and the crystal structures of three inhibitor complexes were determined. The crystal structures revealed that one inhibitor (NSC 18508) occupies only the S1 subsite, while two other inhibitors (NSC 89167 and NSC 251810) bind only to the prime part of the substrate-binding site. One of the major conformational changes observed in all three caspase-3-inhibitor complexes is a rotation of the Tyr204 side chain, which blocks the S2 subsite. In addition, the structural variability of the residues shaping the S1-S4 as well as the S1' subsites supports an induced-fit mechanism for the binding of the inhibitors in the active site. The high-resolution crystal structures reported here provide novel insights into the architecture of the substrate-binding site, which might be useful for the design of more potent caspase inhibitors.

[1]  M. Grütter,et al.  Studies of the molecular mechanism of caspase-8 activation by solution NMR , 2010, Cell Death and Differentiation.

[2]  Amedeo Caflisch,et al.  Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. , 2009, Journal of medicinal chemistry.

[3]  M. Grütter,et al.  Structural and biochemical studies on procaspase-8: new insights on initiator caspase activation. , 2009, Structure.

[4]  A. Caflisch,et al.  Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. , 2006, Journal of medicinal chemistry.

[5]  J. Mikolajczyk,et al.  Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10. , 2006, Journal of medicinal chemistry.

[6]  M. Grütter,et al.  Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors. , 2006, Biochemistry.

[7]  Markus G Grütter,et al.  Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis. , 2006, Journal of molecular biology.

[8]  Egon L. Willighagen,et al.  The Blue Obelisk—Interoperability in Chemical Informatics , 2006, J. Chem. Inf. Model..

[9]  W. McCluggage,et al.  Ectopic Prostatic Tissue in the Uterine Cervix and Vagina: Report of a Series With a Detailed Immunohistochemical Analysis , 2006, The American journal of surgical pathology.

[10]  G. Salvesen,et al.  The protein structures that shape caspase activity, specificity, activation and inhibition. , 2004, The Biochemical journal.

[11]  J. Mikolajczyk,et al.  Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. , 2004, Journal of medicinal chemistry.

[12]  Peter Kolb,et al.  Automated docking of highly flexible ligands by genetic algorithms: A critical assessment , 2004, J. Comput. Chem..

[13]  Christophe Briand,et al.  Crystal Structure of Caspase-2, Apical Initiator of the Intrinsic Apoptotic Pathway* , 2003, Journal of Biological Chemistry.

[14]  S. Piana,et al.  Structure-based thermodynamic analysis of caspases reveals key residues for dimerization and activity. , 2003, Biochemistry.

[15]  Daniel A Erlanson,et al.  Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. , 2002, Journal of medicinal chemistry.

[16]  A. Caflisch,et al.  Fragment-Based Flexible Ligand Docking by Evolutionary Optimization , 2001, Biological chemistry.

[17]  A. Caflisch,et al.  Efficient electrostatic solvation model for protein‐fragment docking , 2001, Proteins.

[18]  M. Grütter,et al.  Caspases: key players in programmed cell death. , 2000, Current opinion in structural biology.

[19]  A Caflisch,et al.  Hydrophobicity at the surface of proteins , 1999, Proteins.

[20]  J. Apostolakis,et al.  Exhaustive docking of molecular fragments with electrostatic solvation , 1999, Proteins.

[21]  M. Karplus,et al.  Docking by Monte Carlo minimization with a solvation correction: Application to an FKBP—substrate complex , 1997 .

[22]  M. Grütter,et al.  Structure of Recombinant Human CPP32 in Complex with the Tetrapeptide Acetyl-Asp-Val-Ala-Asp Fluoromethyl Ketone* , 1997, The Journal of Biological Chemistry.

[23]  Mark A. Murcko,et al.  Structure and mechanism of interleukin-lβ converting enzyme , 1994, Nature.

[24]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[25]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[26]  Harold A. Scheraga,et al.  Determination of net atomic charges using a modified partial equalization of orbital electronegativity method. 1. Application to neutral molecules as models for polypeptides , 1990 .